Patents by Inventor Danielle Elizabeth DETTLING

Danielle Elizabeth DETTLING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC ANTIGEN RECEPTORS TARGETING FLT3
    Publication number: 20230181634
    Abstract: Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).
    Type: Application
    Filed: May 31, 2018
    Publication date: June 15, 2023
    Inventors: Barbra Johnson SASU, Danielle Elizabeth DETTLING, Cesar Adolfo SOMMER, Yik Andy YEUNG, Moustafa Marc HAMZE
  • ANTIBODIES SPECIFIC FOR FLT3 AND THEIR USES
    Publication number: 20230059489
    Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
    Type: Application
    Filed: June 24, 2022
    Publication date: February 23, 2023
    Inventors: Danielle Elizabeth DETTLING, Yik Andy YEUNG, Kristian Todd POULSEN, Veena KRISHNAMOORTHY, Cesar Adolfo SOMMER
  • Antibodies specific for FLT3 and their uses
    Patent number: 11421040
    Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 23, 2022
    Assignee: Pfizer Inc.
    Inventors: Danielle Elizabeth Dettling, Yik Andy Yeung, Kristian Todd Poulsen, Veena Krishnamoorthy, Cesar Adolfo Sommer
  • ANTIBODIES SPECIFIC FOR FLT3 AND THEIR USES
    Publication number: 20180346601
    Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
    Type: Application
    Filed: May 31, 2018
    Publication date: December 6, 2018
    Applicant: PFIZER INC.
    Inventors: Danielle Elizabeth DETTLING, Yik Andy YEUNG, Kristian Todd POULSEN, Veena KRISHNAMOORTHY, Cesar Adolfo SOMMER